Correction Biopharmaceutical (Hangzhou) Research Institute

Correction Biopharmaceutical (Hangzhou) Co., Ltd. is a clinical-stage biotechnology company based in China, specializing in the discovery and development of innovative small molecule therapeutics for metabolic and inflammatory diseases. The company's primary focus is on addressing unmet medical needs in the treatment of hyperuricemia and gout through the development of highly selective and potent inhibitors. Its lead candidate, CBW647, is a novel URAT1 inhibitor designed to provide superior efficacy and safety compared to existing uricosuric agents. Correction Biopharmaceutical leverages its internal research institute to advance a pipeline of metabolic-focused drug candidates from discovery through clinical validation.